First Wave BioPharma Inc (FWBI)

NASDAQ
0.3675
+0.0074(+2.06%)
After Hours
0.3610
-0.0065(-1.7687%)
- Real-time Data
  • Volume:
    87,773
  • Day's Range:
    0.3520 - 0.3800
  • 52 wk Range:
    0.2800 - 9.7000

FWBI Overview

Prev. Close
0.3601
Day's Range
0.352-0.38
Revenue
-
Open
0.352
52 wk Range
0.28-9.7
EPS
-11.19
Volume
87,773
Market Cap
7.95M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
893,939
P/E Ratio
-
Beta
1.79
1-Year Change
-95.61%
Shares Outstanding
21,635,338
Next Earnings Date
Jun 01, 2022
What is your sentiment on First Wave BioPharma?
or
Market is currently closed. Voting is open during market hours.

First Wave BioPharma Inc News

First Wave BioPharma Inc Analysis

First Wave BioPharma Inc Company Profile

First Wave BioPharma Inc Company Profile

Employees
12

First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties; and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn’s disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuyBuySellStrong Sell
Technical IndicatorsStrong BuyStrong BuyBuySellStrong Sell
SummaryStrong BuyStrong BuyBuySellStrong Sell
  • It’s show time! 🔥
    0
    • Korea Bio company, Hyundai IBT, starts clinical trial based on niclosimide and its own drug delivery system technology. It may have amazing efficacy. Where is aarket for AZRX(FWBI)?
      0
      • due to reverse split buy price is 5.8. almost 40% loss. :(
        0
        • You mean 2.80 or 70% loss!
          0
      • Whats going on…?
        0
        • After september 23 new name FWBI
          0
          • https://www.marketwatch.com/amp/story/azurrx-biopharma-to-buy-first-wave-bio-for-229m-in-cash-stock-271631528016
            0
            • What the hell?
              0
              • Reverse split
                0
            • Reverse split? Or extraordinary pump? Since 2021 i dont believe in miracles haha
              0
              • 1:10 Reverse split
                0
            • This stock like to stay qroud. 0.50 - 0.55
              0
              • bought 500 at .5890. hold or sell. advice plZ
                0
                • hold do not sell this will jump anytime now target 3
                  0